Leyden Labs was covered as Emerging Company Profile by Scrip. Sten Stovall discusses in his article how our novel intranasal medicine can potentially target viral families to prevent the next pandemic.
Last month, our CEO Koenraad Wiedhaup spoke with co-founder and editor of MedNous, Victoria English, about Leyden Labs. They discussed the development of our platform and portfolio of prophylactic nasal sprays and their potential role to prevent future pandemics.
Victor Kotsev has evaluated a broad range of initiatives following the COVID-19 pandemic. He also highlights Leyden Labs' proactive approach toward viral diseases amongst a range of vaccine and treatment options.
Heather McKenzie recently wrote an article about pandemic preparedness. She explores future threats and a collection of measures to protect against future outbreaks. You can read the full article on the BioSpace website.
Learn more about our story in the conversation between Koenraad Wiedhaup (CEO) and David Schenkein (General Partner at GV and board member at Leyden Labs). They discuss the mission and approach, investment round, fantastic team and plans for the future.
The passing of John Martin, who served as a member of our Supervisory Board came unexpectedly and has left us with great sadness. Our thoughts are with his family and his friends.
Cormac Sheridan wrote an article about our investment round with GV (formerly Google Ventures), F-Prime, Casdin Capital and Brook Byers. To learn more about our Series A and our story, visit the BioWorld website.
Leading up to the public launch, our CEO Koenraad Wiedhaup spoke with Amber Tong of Endpoints News about Leyden Labs. An interesting read to learn more about our mission to free humanity from the burden of respiratory viruses.
Funding to advance platform and portfolio of intranasal products that protect against a broad range of respiratory viruses, including influenza and coronaviruses, to let people live their lives freely